№ files_lp_3_process_9_41378
File format: docx
Character count: 3036
File size: 1168 KB
This document is a current report filed by CNS Pharmaceuticals, Inc. with the U.S. Securities and Exchange Commission, detailing financial and operational updates, including share sales and an investor presentation.
Year:
2025
Region / City:
Washington, D.C.
Subject:
Securities Exchange Act Filing
Document Type:
Report
Organization / Institution:
United States Securities and Exchange Commission
Author:
CNS Pharmaceuticals, Inc.
Target Audience:
Investors, SEC
Period of Validity:
January 3, 2025
Date of Approval:
January 3, 2025
Date of Amendments:
None
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2022
Region / City:
United States
Subject:
Extension of Maturity Date for Credit Agreement
Document Type:
Financial Report
Organization:
Toyota Motor Credit Corporation
Author:
Toyota Motor Credit Corporation
Target Audience:
Investors, Financial Analysts
Period of Validity:
November 4, 2022
Approval Date:
November 4, 2022
Amendment Date:
Not Applicable
Year:
2026
Date of Report:
January 28, 2026
Date of Earliest Event Reported:
January 23, 2026
Company:
Louisiana-Pacific Corporation
State of Incorporation:
Delaware
Commission File Number:
1-7107
IRS Employer Identification No.:
93-0609074
Principal Executive Offices:
1610 West End Ave, Suite 200, Nashville, TN 37203
Telephone:
(615) 986-5600
Exchange:
New York Stock Exchange
Trading Symbol:
LPX
Securities Registered:
Common Stock, $1 par value
Regulatory Authority:
Securities and Exchange Commission
Governing Law:
Securities Exchange Act of 1934
Reporting Form:
Form 8-K
Items Reported:
Item 5.02; Item 7.01; Item 9.01
Subject Matter:
Retirement and appointment of directors; board succession planning; press release disclosure; forward-looking statements
Signatory:
Leslie E. Davis, Vice President, Controller and Chief Accounting Officer
Signature Date:
January 28, 2026
Year:
2019
Date of Report:
October 22, 2019
Date of Earliest Event Reported:
October 17, 2019
Company:
AbbVie Inc.
State of Incorporation:
Delaware
IRS Employer Identification No.:
32-0375147
Commission File Number:
001-35565
Principal Executive Offices:
1 North Waukegan Road, North Chicago, Illinois 60064-6400
Telephone:
(847) 932-7900
Stock Exchange Listings:
New York Stock Exchange; Chicago Stock Exchange
Trading Symbols:
ABBV; ABBV24; ABBV27; ABBV28; ABBV31
Securities Registered:
Common Stock, $0.01 Par Value; 1.375% Senior Notes due 2024; 0.750% Senior Notes due 2027; 2.125% Senior Notes due 2028; 1.250% Senior Notes due 2031
Legal Basis:
Securities Exchange Act of 1934
Reporting Form:
Form 8-K
Items Reported:
Item 5.03; Item 9.01
Governing Law Referenced:
General Corporation Law of the State of Delaware
Board Action Date:
October 17, 2019
Signatory:
Laura J. Schumacher, Vice Chairman, External Affairs, Chief Legal Officer, and Corporate Secretary
Exhibit:
Amended and Restated By-laws of AbbVie Inc. adopted on October 17, 2019
Year:
2025
Region / City:
Washington, D.C.
Subject:
Corporate Financial Reporting
Document Type:
Report
Organization / Institution:
United States Securities and Exchange Commission
Author:
AbbVie Inc.
Target Audience:
Investors, Financial Analysts, Regulators
Effective Period:
January 30, 2025 – January 30, 2030
Approval Date:
January 30, 2025
Amendment Date:
N/A
Year:
2009
Region / City:
Washington, DC
Topic:
Corporate Governance
Document Type:
Report
Organization:
General Motors Company
Author:
Not specified
Target Audience:
Investors, Shareholders
Period of Validity:
July 20, 2009
Approval Date:
July 20, 2009
Amendment Date:
Not specified
Note:
Description
Year:
2010
Date of Report:
April 12, 2010
Filing Date:
April 14, 2010
Document Type:
Current Report on Form 8-K
Regulatory Authority:
Securities Exchange Act of 1934
Issuing Authority:
United States Securities and Exchange Commission
Registrants:
Exelon Corporation; PECO Energy Company
State of Incorporation:
Pennsylvania
Principal Executive Offices:
Chicago, Illinois; Philadelphia, Pennsylvania
Subject Matter:
Entry into a Material Definitive Agreement; Smart Grid Investment Grant
Government Agency Involved:
U.S. Department of Energy
Program:
Smart Grid Investment Grant under the American Recovery and Reinvestment Act
Award Number:
DE-OE0000207
Grant Amount:
$200 million
Project Name:
Smart Future Greater Philadelphia
Period of Performance:
December 24, 2009 through December 23, 2014
Signatories:
Matthew F. Hilzinger; Phillip S. Barnett
Year:
2025
Region / City:
Washington, D.C.
Subject:
Corporate Finance, Securities Filing
Document Type:
SEC Filing
Organization / Institution:
U.S. Securities and Exchange Commission
Author:
Sabre Corporation
Target Audience:
Investors, Financial Analysts, Legal and Compliance Professionals
Period of Effect:
December 5, 2025
Approval Date:
December 5, 2025
Date of Amendments:
None
Year:
2025
Region / City:
Southlake, TX
Theme:
Corporate Disclosure, Financial Reporting
Document Type:
Corporate Filing
Organ / Institution:
Sabre Corporation
Author:
Sabre Corporation
Target Audience:
Investors, Securities Regulators
Period of Validity:
Until December 23, 2025
Approval Date:
December 23, 2025
Amendment Date:
None
Year:
2022
Region / City:
United States, Washington, DC
Topic:
Corporate Financial Reporting
Document Type:
Report
Organization / Institution:
United States Securities and Exchange Commission
Author:
General Motors Company
Target Audience:
Investors, Securities Analysts
Period of Action:
Q4 2021, Full Year 2021
Date of Approval:
February 1, 2022
Date of Changes:
N/A
Year:
2025
Date of Report:
November 4, 2025
Reporting Period:
Quarter ended September 30, 2025
Company:
Synchronoss Technologies, Inc.
State of Incorporation:
Delaware
Commission File Number:
001-40574
IRS Employer Identification Number:
06-1594540
Headquarters Address:
200 Crossing Boulevard, 8th Floor, Bridgewater, New Jersey 08807
Telephone:
(866) 620-3940
Exchange:
The Nasdaq Stock Market, LLC
Trading Symbol:
SNCR
Securities Registered:
Common Stock, par value $.0001
Chief Executive Officer:
Jeffrey Miller
Exhibit:
Press Release dated November 4, 2025 announcing Third Quarter 2025 results
Year:
2023
Region / city:
United States, United Kingdom
Subject:
Credit agreement amendment and performance letter of credit facility
Document type:
Corporate filing
Organization / institution:
TechnipFMC plc
Author:
Not specified
Target audience:
Investors, financial analysts, regulatory authorities
Effective period:
From April 24, 2023
Date of approval:
April 24, 2023
Date of changes:
Not specified
Year:
2024
Region / City:
United States
Theme:
Corporate Agreement, Distribution Agreement
Document Type:
SEC Filing
Organization / Institution:
United States Securities and Exchange Commission
Author:
QT Imaging Holdings, Inc.
Target Audience:
Investors, Financial Analysts, Corporate Stakeholders
Period of Effect:
June 10, 2024 – December 31, 2025
Date of Approval:
June 18, 2024
Date of Amendments:
N/A
Context:
Official SEC filing outlining the transition from a Sales Agent Agreement to a Distribution Agreement between QT Imaging Holdings, Inc. and NXC Imaging, Inc.
Year:
2020
Region / City:
United States
Theme:
Securities Filing, Financial Disclosure
Document Type:
Official Report
Organization:
United States Securities and Exchange Commission
Author:
American Airlines Group Inc.
Target Audience:
Investors, Securities Regulators
Period of Validity:
November 2020
Approval Date:
November 10, 2020
Date of Changes:
November 10, 2020
Year:
2017
Country:
United States
Organization:
Alliance Data Systems Corporation
Document Type:
Current Report (Form 8-K)
Regulatory Authority:
U.S. Securities and Exchange Commission
Legal Basis:
Securities Exchange Act of 1934 (Sections 13 and 15(d))
Date of Report:
October 19, 2017
Reporting Period:
Quarter ended September 30, 2017
Headquarters Location:
Plano, Texas, United States
Industry:
Data-driven marketing and loyalty solutions
Key Financial Metrics:
Revenue, Net Income, Earnings Per Share, Adjusted EBITDA
Related Materials:
Press Release (Exhibit 99.1); Investor Presentation Materials (Exhibit 99.2)
Signatory:
Charles L. Horn, Executive Vice President and Chief Financial Officer
Year:
2025
Region / City:
Greenwich, Connecticut
Subject:
Corporate Announcement
Document Type:
SEC Filing
Organization:
GXO Logistics, Inc.
Author:
GXO Logistics, Inc.
Target Audience:
Investors, Regulators
Period of Action:
2025
Approval Date:
June 19, 2025
Amendment Date:
Not Applicable
Year:
2025
Jurisdiction:
Texas, United States
Subject:
Criminal justice information systems operations and access
Document type:
Operational manual
Issuing body:
Texas Department of Public Safety
Systems covered:
Texas Crime Information Center; Texas Law Enforcement Telecommunications System; National Crime Information Center; Nlets
Bureau:
Compliance and Training Bureau
Access level:
Sensitive but unclassified
Intended audience:
Law enforcement agencies and criminal justice administrators
Effective date:
January 1, 2025
Contact information:
[email protected]
Year:
2023
Region / City:
Georgia
Topic:
Drug management, Isoflurane usage
Document Type:
Instructional form
Organization / Institution:
Georgia Board of Pharmacy
Author:
Georgia Board of Pharmacy
Target Audience:
Registrants (licensed distributors, manufacturers, and dispensers of dangerous drugs)
Effective Period:
2023 - ongoing
Approval Date:
N/A
Modification Date:
N/A
Year:
2025
Region / City:
United States
Theme:
Church governance
Document type:
Constitution
Organization / Institution:
Evangelical Lutheran Church in America (ELCA)
Author:
Evangelical Lutheran Church in America
Target audience:
Congregations of the Evangelical Lutheran Church in America
Effective period:
As of August 2025
Approval date:
August 2025
Amendment date:
2025
Contextual description:
A governing document outlining the structure, requirements, and flexibility for congregations of the Evangelical Lutheran Church in America.
Year:
2024
Region / City:
Canada
Subject:
Lawyer licensing process updates
Document Type:
Webcast script
Institution:
Law Society
Author:
Law Society
Target Audience:
Current lawyer licensing candidates
Effective Period:
Summer 2024
Approval Date:
N/A
Modification Date:
N/A
Year:
2021
Region / City:
N/A
Topic:
Healthcare, Aging, Senior Care
Document Type:
Implementation Tool
Organization / Institution:
N/A
Author:
N/A
Target Audience:
Healthcare providers, Senior Care Organizations
Effective Period:
N/A
Approval Date:
N/A
Date of Changes:
N/A